Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Study to Assess the Safety and Tolerability of Multiple Dose Levels and Multiple Dosing Regimens of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

NCT00433147 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.

NCT NCT00433147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00433147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Study to Assess the Safety and Tolerability of Multiple Dose Levels and Multiple Dosing Regimens of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy
Lead sponsor
Amicus Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
March 23, 2007
Completion date
February 19, 2008
Enrollment
30 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease, gaucher disease, type 1, type 1 gaucher disease